Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Assets: 2023-2025

Historic Return on Assets for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to 0.05%.

  • Monte Rosa Therapeutics' Return on Assets rose 41.00% to 0.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year increase of 41.00%. This contributed to the annual value of -0.20% for FY2024, which is N/A change from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Return on Assets stood at 0.05%, which was down 20.40% from 0.06% recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Return on Assets peaked at 0.06% during Q2 2025, and registered a low of -0.49% during Q4 2023.
  • Its 3-year average for Return on Assets is -0.23%, with a median of -0.28% in 2024.
  • Data for Monte Rosa Therapeutics' Return on Assets shows a peak YoY spiked of 49bps (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Return on Assets stood at -0.49% in 2023, then increased by 29bps to -0.19% in 2024, then skyrocketed by 41bps to 0.05% in 2025.
  • Its Return on Assets was 0.05% in Q3 2025, compared to 0.06% in Q2 2025 and 0.01% in Q1 2025.